Published in Gene Therapy Weekly, May 26th, 1997
Researchers from Vion Pharmaceuticals and Yale University School of Medicine have determined that certain manipulated strains of S. typhimurium selectively target and kill tumor cells (see stories in this issue). To better understand the mechanisms of tumor retardation by Salmonella, S.K. Kops and colleagues conducted microscopic exams of the effects of S. typhimurium mutant M2 in murine cancer models. Their results were presented at the American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.